Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Sunny Pharmtech's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6676 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Sunny Pharmtech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunny Pharmtech Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunny Pharmtech's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sunny Pharmtech's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunny Pharmtech (ROCO:6676) has a Buyback Yield % of -0.39 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sunny Pharmtech and its competitors. According to the industry distribution chart, Sunny Pharmtech ranks #175 out of 738 companies in the Biotechnology industry, placing it in the top 23.7%.
Is Sunny Pharmtech's Buyback Yield % too high?
Sunny Pharmtech's current Buyback Yield % is -0.39. Based on the distribution chart, Sunny Pharmtech ranks #175 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunny Pharmtech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sunny Pharmtech's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunny Pharmtech ranks #175 out of 738 companies for Buyback Yield %. This places Sunny Pharmtech in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sunny Pharmtech and its competitors. Sunny Pharmtech's current Buyback Yield % is -0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunny Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sunny Pharmtech (ROCO:6676) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.40, compared to a current price of NT$12.90 — trading 3.7% below its estimated fair value. The current Buyback Yield % is -0.39. Sunny Pharmtech's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sunny Pharmtech (ROCO:6676), the current Buyback Yield % is -0.39 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunny Pharmtech (ROCO:6676) Overvalued in 2026?
Based on GuruFocus' analysis, Sunny Pharmtech stock appears to be undervalued.
The current stock price of NT$12.90 is trading 3.7% below its estimated GF Value™ of NT$13.40.
GuruFocus considers Sunny Pharmtech to be Fairly Valued.
Key valuation signals for ROCO:6676:
Buyback Yield %: -0.39
GF Value™: NT$13.40 vs. price of NT$12.90 (3.7% below fair value)
No single metric tells the full story. See the ROCO:6676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.
59GF Score
Get the complete analysis for ROCO:6676
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6676 has been successfully added to your 
